Literature DB >> 26678178

Identification, isolation and characterization of potential process-related impurity and its degradation product in vildagliptin.

Neeraj Kumar1, Subba Rao Devineni1, Gurmeet Singh2, A Kadirappa1, Shailendra Kumar Dubey1, Pramod Kumar3.   

Abstract

Vildagliptin is a member of a new class of oral anti-diabetic drug. One unknown impurity was identified in the range of 0.01-0.06% in different laboratory batches of vildagliptin along with known impurities by HPLC analysis. The structure of unknown impurity was proposed as (2S)-1-[2-[(3-hydroxyadamantan-1-yl)imino]acetyl]pyrrolidine-2-carbonitrile (Impurity-E) using LC/ESI-MS(n) study. The unknown impurity was found to be unstable in diluent (H2O:CH3CN) and degrading into another stable impurity. The degraded stable impurity was isolated from enriched reaction crude sample by semi preparative liquid chromatography. The structure of stable impurity was established using FT-IR, NMR ((1)H, (13)C and DEPT), 2D NMR (HSQC, HMBC and COSY) and mass spectral data as (8aS)-3-hydroxy-octahydropyrrolo[1,2-a]piperazine-1,4-dione (Impurity-F). Impurity identification, abnormal behaviour of impurity-E, isolation of impurity-F, fragmentation mechanism and structural elucidation were also discussed.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Identification; Impurity degradation; Isolation; LC/ESI–MS(n); NMR; Vildagliptin

Mesh:

Substances:

Year:  2015        PMID: 26678178     DOI: 10.1016/j.jpba.2015.11.044

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  2 in total

1.  Synthesis, isolation, identification and characterization of new process-related impurity in isoproterenol hydrochloride by HPLC, LC/ESI-MS and NMR.

Authors:  Neeraj Kumar; Subba Rao Devineni; Prasad Reddy Gajjala; Shailendra Kumar Dubey; Pramod Kumar
Journal:  J Pharm Anal       Date:  2017-05-10

2.  Physicochemical Properties and Methods of Analysis of Vildagliptin (Review).

Authors:  E B Polyakova; D R Sabirzyanov; N A Prozorova; A V Foteeva
Journal:  Pharm Chem J       Date:  2022-03-30       Impact factor: 1.063

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.